Search - tctmd.com

Displaying 121 - 140 of 156

Sort: Relevancy | Date

Stent Thrombosis and Restenosis

Presentation Fellows 2017

Stent Thrombosis and Restenosis

Presenter: Emmanouil S. Brilakis, Ajay J. Kirtane

April 08, 2017

Monthly Vitamin D Fails to Prevent CVD in Large Randomized Trial

News Daily News

Monthly Vitamin D Fails to Prevent CVD in Large Randomized Trial

April 07, 2017

Absorb BVS Use Restricted in Europe

News Daily News

Absorb BVS Use Restricted in Europe

Michael O'Riordan

April 06, 2017

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

News Daily News

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

Michael O'Riordan

March 29, 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

News Conference News ACC 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Michael O'Riordan

March 19, 2017

Live From Washington: ACC 2017, Day Three

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Three

March 19, 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

News Conference News ACC 2017

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Michael O'Riordan

March 18, 2017

iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions

News Conference News ACC 2017

iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions

March 18, 2017

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

News Conference News ACC 2017

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

March 18, 2017

Rivaroxaban Bests Aspirin for Preventing Recurrence of VTE: EINSTEIN CHOICE

News Conference News ACC 2017

Rivaroxaban Bests Aspirin for Preventing Recurrence of VTE: EINSTEIN CHOICE

March 18, 2017

Focused Update to Valve Guidelines Tackles Intermediate-Risk TAVR, Anticoagulation for A-fib

News Daily News

Focused Update to Valve Guidelines Tackles Intermediate-Risk TAVR, Anticoagulation for A-fib

March 15, 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

Faster Primary PCIs Linked to Higher Stent Thrombosis Risk With Bivalirudin

News Daily News

Faster Primary PCIs Linked to Higher Stent Thrombosis Risk With Bivalirudin

March 07, 2017

Length Matters: More Adverse Events With Absorb BVS at 1 Year in Long Lesions

News Daily News

Length Matters: More Adverse Events With Absorb BVS at 1 Year in Long Lesions

March 02, 2017

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

News Conference News CRT 2017

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

Michael O'Riordan

February 21, 2017

DESolve Bioresorbable Stent Compares Well With Absorb but Longer Follow-up Needed

News Daily News

DESolve Bioresorbable Stent Compares Well With Absorb, but Longer Follow-up Needed

Michael O'Riordan

February 16, 2017

Percutaneous Bypass for Long, Complex SFA Lesions Holds Up Well to 6 Months: DETOUR I Study

News Conference News ISET 2017

Percutaneous Bypass for Long, Complex SFA Lesions Holds Up Well to 6 Months: DETOUR I Study

February 10, 2017

The EluNIR clinical program: BIONICS and NIREUS - One Year Follow Up

Presentation JIM 2017

The EluNIR clinical program: BIONICS and NIREUS - One Year Follow Up

Presenter: Giuseppe Musumeci

February 09, 2017

Rivaroxaban’s “Overwhelming” Efficacy for Coronary, Peripheral Disease Leads to Early Halt of COMPASS

News Daily News

Rivaroxaban’s ‘Overwhelming’ Efficacy for Coronary, Peripheral Disease Leads to Early Halt of COMPASS

February 08, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.